These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38731175)

  • 1. Major Orthopaedic Surgery in Persons with Haemophilia A with and without Inhibitors Treated by Emicizumab: A Mid-Term, Large, and Successful Series at a Single Center.
    Carulli C; Daniele G; Linari S; Pieri L; Littera M; Mazzetti M; Tamburini C; Prisco D; Castaman G
    J Clin Med; 2024 Apr; 13(9):. PubMed ID: 38731175
    [No Abstract]   [Full Text] [Related]  

  • 2. Joint replacement for the management of haemophilic arthropathy in patients with inhibitors: A long-term experience at a single Haemophilia centre.
    Carulli C; Innocenti M; Linari S; Morfini M; Castaman G; Innocenti M
    Haemophilia; 2021 Jan; 27(1):e93-e101. PubMed ID: 32997896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emicizumab prophylaxis in haemophilia A with inhibitors: Three years follow-up from the UK Haemophilia Centre Doctors' Organisation (UKHCDO).
    Wall C; Xiang H; Palmer B; Chalmers E; Chowdary P; Collins PW; Fletcher S; Hall GW; Hart DP; Mathias M; Sartain P; Shapiro S; Stephensen D; Talks K; Hay CRM;
    Haemophilia; 2023 May; 29(3):743-752. PubMed ID: 36811304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Total Knee Arthroplasty in Haemophilia: Long-Term Results and Survival Rate of a Modern Knee Implant with an Oxidized Zirconium Femoral Component.
    Carulli C; Innocenti M; Tambasco R; Perrone A; Civinini R
    J Clin Med; 2023 Jun; 12(13):. PubMed ID: 37445391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes and patient satisfaction following total hip and knee arthroplasty in patients with inherited bleeding disorders: A 20-year single-surgeon cohort.
    Anderson JA; Mason JA; Halliday B
    Haemophilia; 2018 Sep; 24(5):786-791. PubMed ID: 30024636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B.
    Olasupo OO; Noronha N; Lowe MS; Ansel D; Bhatt M; Matino D
    Cochrane Database Syst Rev; 2024 Feb; 2(2):CD014544. PubMed ID: 38411279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcome of total hip arthroplasty in patients with haemophilia.
    Strauss AC; Rommelspacher Y; Nouri B; Bornemann R; Wimmer MD; Oldenburg J; Pennekamp PH; Schmolders J
    Haemophilia; 2017 Jan; 23(1):129-134. PubMed ID: 27480604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Total hip and knee arthroplasty in HIV- and HCV-positive hemophilia patients: short term follow-up of 14 patients.
    Wang Z; Gu Y; Wang R; Xiang S; Jin Z; Tong P; Lv S; Liu X
    BMC Musculoskelet Disord; 2023 Dec; 24(1):946. PubMed ID: 38057748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends of outcomes and healthcare utilization following orthopaedic procedures in adults with haemophilia: A 3-decade retrospective review.
    Lin CY; Hosseini F; Squire S; Jackson S; Sun HL
    Haemophilia; 2022 Jan; 28(1):151-157. PubMed ID: 34730853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low rate of subclinical venous thrombosis in patients with haemophilia undergoing major orthopaedic surgery in the absence of pharmacological thromboprophylaxis.
    Verstraete G; Lambert C; Hammer F; Hermans C
    Haemophilia; 2020 Nov; 26(6):1064-1071. PubMed ID: 33339074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. When should prophylactic treatment in patients with haemophilia A and B start?--The German experience.
    Kreuz W; Escuriola-Ettingshausen C; Funk M; Schmidt H; Kornhuber B
    Haemophilia; 1998 Jul; 4(4):413-7. PubMed ID: 9873763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Our experience with revision total knee arthroplasty].
    Musil D; Stehlík J; Stárek M
    Acta Chir Orthop Traumatol Cech; 2005; 72(1):6-15. PubMed ID: 15860146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study.
    Oldenburg J; Mahlangu JN; Bujan W; Trask P; Callaghan MU; Young G; Asikanius E; Peyvandi F; Santagostino E; Kruse-Jarres R; Negrier C; Kessler C; Xu J; Windyga J; Shima M; von Mackensen S
    Haemophilia; 2019 Jan; 25(1):33-44. PubMed ID: 30427582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safe and Successful Surgical Outcome in Persons with Hemophilia A with and without Inhibitors Treated with Emicizumab: A Large, Single Center, Real-World Experience.
    Castaman G; Linari S; Pieri L; Carulli C; Prosperi P; Tonelli P; Demartis F; Fjerza R; Attanasio M; Coppo M; Salvianti F
    J Clin Med; 2023 Mar; 12(6):. PubMed ID: 36983317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study.
    Kiialainen A; Niggli M; Kempton CL; Castaman G; Chang T; Paz-Priel I; Adamkewicz JI; Levy GG
    Haemophilia; 2022 Nov; 28(6):1033-1043. PubMed ID: 35905294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Excellent mid- to long-term survival of tantalum metal cones in a case series of revision knee arthroplasty with severe bony defects.
    Eder-Halbedl M; Fink A; Pietsch M; Djahani O; Hofmann S
    Knee Surg Sports Traumatol Arthrosc; 2023 Dec; 31(12):5496-5506. PubMed ID: 37819600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
    Pipe SW; Shima M; Lehle M; Shapiro A; Chebon S; Fukutake K; Key NS; Portron A; Schmitt C; Podolak-Dawidziak M; Selak Bienz N; Hermans C; Campinha-Bacote A; Kiialainen A; Peerlinck K; Levy GG; Jiménez-Yuste V
    Lancet Haematol; 2019 Jun; 6(6):e295-e305. PubMed ID: 31003963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of bleeding events and invasive procedures in patients with haemophilia A without inhibitors treated with emicizumab.
    Fontana P; Alberio L; Albisetti M; Angelillo-Scherrer A; Asmis LM; Casini A; Gerber B; Graf L; Hegemann I; Korte W; Martinez M; Studt JD; Tsakiris DA; Wuillemin WA; Kremer Hovinga JA
    Swiss Med Wkly; 2020 Dec; 150():w20422. PubMed ID: 33338252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of joint damage in hemophilic children with early prophylaxis.
    Kreuz W; Escuriola Ettingshausen C; Funk M; Pons S; Schmidt H; Kornhuber B
    Orthopade; 1999 Apr; 28(4):341-346. PubMed ID: 28246905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis.
    Batsuli G; Zimowski KL; Tickle K; Meeks SL; Sidonio RF
    Haemophilia; 2019 Sep; 25(5):789-796. PubMed ID: 31373431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.